

15 JUN 2004

15 JUN 2004



T/GB 2004 / 000104



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 16 FEB 2004


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 4 February 2004

BEST AVAILABLE COPY

15JAN03 E777194-1 D10100
P01/7700 0.00-0300885.1

The Patent Office

15 JAN 2003

Cardiff Road
Newport
South Wales
NP10 8QQ**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

CG/P/215/GBA

2. Patent application number

(The Patent Office will fill in this part)

0300885.1

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

The Secretary of State for Defence

DSTL

Porton Down

Salisbury

Wiltshire

SP4 0JQ

GB

6997670005

Patents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

Pharmaceutical Composition

5. Name of your agent (*if you have one*)

Carol P. Greaves et al.

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)Greaves Brewster
Indigo House, Cheddar Business Park
Wedmore Road
Cheddar, Somerset
BS27 3EB

788 S908002

Patents ADP number (*if you know it*)6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application numberCountry Priority application number
(*if you know it*) Date of filing
(*day / month / year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application Date of filing
(*day / month / year*)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

Yes

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description	8
Claim(s)	2
Abstract	1
Drawing(s)	<i>JK</i> 2 + 2

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

One

Request for substantive examination
(*Patents Form 10/77*)

**Any other documents
(please specify)**

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

[Signature] 14/11/03

12. Name and daytime telephone number of person to contact in the United Kingdom

Carol Greaves 01934 745880

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Pharmaceutical Composition

The present invention relates to pharmaceutical compositions, and in particular to compositions comprising immunogens, used in the prophylactic and therapeutic treatment of infections.

The option to self administer vaccines by inhalation, for example using a nebulizer or inhaler such as a dry powder inhaler, would be advantageous from a logistical standpoint and may be particularly effective for protecting individuals from pathogens that affect or utilise the respiratory tract as a portal of entry into the body.

However, administration of in particular non-living vaccines, such as sub-unit vaccines, has not yet been found to be effective.

The applicants have found that biodegradable microspheres, containing antigen, can engender immunological responses following delivery to experimental animals in the form of an aerosol.

According to the present invention there is provided an aerosol formulation comprising a biodegradable microsphere containing a non-living reagent that produces a protective immune response in a host mammal to whom it is administered.

As used herein, the term "non-living reagent" refers to immunogens such as polypeptides or proteins, which are derived for example from a pathogen such as a bacteria, virus or fungi. It also refers to inactivated micro-organisms such as heat or chemically killed bacteria and/or viruses.

These formulations are effective in the administration of reagents, which are capable of generating a protective immune response in an animal, particularly a mammal, to which it is administered. Examples of such agents include antigenic

polypeptides as well as nucleic acid sequences which may encode these polypeptides and which are known as "DNA" vaccines.

Suitable polypeptides are sub-unit vaccines and others, such as
5 diphtheria toxoid, tetanus toxoid, *Botulinum* toxin FHC and
Bacillus anthracis protective antigen (PA).

As used herein the expression "polypeptide" encompasses proteins or epitopic fragments thereof.

10

Suitable polypeptides are sub-unit vaccines.

In a preferred embodiment, the formulation of the invention comprises a biologically active agent which is capable of
15 generating a protective immune response against *Yersinia pestis*. The agent is suitably a sub-unit vaccine, for example V antigen of *Y. pestis* or an immunologically active fragment thereof or a variant of these, or the F1 antigen of *Y. pestis* or an immunologically active fragment thereof or a variant of these, or
20 a combination of these. In particular as described in WO 96/28551, preferred vaccine comprises a combination of the F1 and V antigens.

As used herein, the term "fragment" refers to a portion of the
25 basic sequence which includes at least one antigenic determinant. These may be deletion mutants. One or more epitopic region of the sequence may be joined together.

The expression "variant" refers to sequences of nucleic acids
30 which differ from the base sequence from which they are derived in that one or more amino acids within the sequence are substituted for other amino acids. Amino acid substitutions may be regarded as "conservative" where an amino acid is replaced with a different amino acid with broadly similar properties.
35 Non-conservative substitutions are where amino acids are replaced with amino acids of a different type. Broadly speaking, fewer

non-conservative substitutions will be possible without altering the biological activity of the polypeptide. Suitably variants will be at least 60% identical, preferably at least 75% identical, and more preferably at least 90% identical to the base sequence. Identity in this case can be determined using available algorithms such as the widely used BLAST program.

The applicants have found that nebulisation of PLA microspheres generates a respirable 'plume' of aerosolised particles, and this approach can be used to deliver immunogens to the respiratory tracts of experimental animals. Similar plumes could be produced using other forms of inhaler such as dry powder inhalers.

Microspheres used are suitably small enough to allow them to be administered to the deep lung using a conventional nebulizer or inhaler. For this purpose, microspheres will suitably be less than 5 μm average diameter, preferably less than 3 μm average diameter and most preferably with an average diameter of between 1 and 1.5 μm .

Microcapsules are suitably biodegradable and are produced from polymeric material. A particularly suitable polymer for use in the preparation of microcapsules is Poly-lactide (PL) although other polymers such as poly(lactide-co-glycolide) PLGA may also be employed.

The microspheres may optionally further comprise agents which stabilise emulsions such as polyvinylalcohol (PVA), dipalmitoyl-phosphatidylcholine (DPPC), or methyl cellulose, and preferably polyvinylalcohol.

Microcapsules are suitably prepared using conventional methods such as the double emulsion/solvent evaporation method, as described for example by Beck et al., 1979, Fertility and Sterility, 31:545-551.

The encapsulation is suitably achieved using a double emulsion solvent evaporation method, in which a first emulsion is formed with the non-living reagent, and the structural polymer, mixing 5 this with an aqueous phase (suitably without structural polymer) to form a secondary emulsion, evaporating solvent and isolating small microspheres. In particular, the pharmaceutically active ingredient is dissolved or suspended in an aqueous solution which optionally includes an emulsifier such as PVA. The emulsifier, 10 where present is suitably included at low concentrations for example of less than 5%w/v. This solution or suspension is then mixed with a solution of the high molecular weight structural polymer in an organic solvent such as dichloromethane. A primary emulsion is then formed, in particular by sonication of the 15 mixture. The primary emulsion is then added to a secondary aqueous phase, which preferably includes an emulsifier with vigorous stirring. Solvent is then preferably evaporated, conveniently at room temperature. Microspheres can then be recovered, for example by centrifugation followed by 20 lyophilisation.

The formulations of the invention may comprise microspheres per se which are optionally preserved, for example by lyophilisation, or the microspheres may be combined with a pharmaceutically acceptable carrier or excipient. Examples of suitable carriers 25 include solid carriers as is understood in the art for use in nebulizers.

The formulation of the invention may further comprise an adjuvant 30 in order to enhance the immune response to the biologically active material administered. Suitable adjuvants include pharmaceutically acceptable adjuvants such as Freund's incomplete adjuvant, alhydrogel, aluminium compounds and, preferably adjuvants which are known to up-regulate mucosal responses such 35 as CTB, the non-toxic pentameric B subunit of cholera toxin (CT).

or mutant heat-labile toxin (mLT) of *E.coli*. They may also include immunomodulators such as cytokines and CpG motifs.

Other adjuvant types are described in International Patent
5 Application Nos. WO00/56282, WO00/56362 and WO00/56361.

Suitably the formulations are in unit dosage form. This will vary depending upon the nature of the active agent being employed, the nature of the patient, the condition being treated
10 and other clinical factors. In general however, the formulations of the invention will comprise approximately 0.5 to 10 w/w of non-living reagent.

Exposed animals, in this case, mice, respond with a humoral
15 response. It has also been found that experimental animals can be protected by this treatment from a lethal challenge with a pathogen such as the plague causing bacteria (*Yersinia. pestis*) by exposure to aerosolised microspheres containing recombinant V antigen. The applicants are therefore the first to demonstrate
20 the successful aerogenic immunisation using non-living vaccines.

Dosages of the formulations of the invention will depend upon various factors such as the the nature of the patient, the antigen used etc. and will be determined according to known
25 clinical practice.

It has been found that in a particularly preferred embodiment, each administration of microsphere preparation to a mouse contains from 1-100 μ g, suitably from 30-50 μ g and most preferably about 40 μ g of each of said antigens. Preferably the dosage to humans and mammals would be of the same order in terms of mg/Kg.
30

According to a further aspect of the invention, there is provided a nebuliser or inhaler comprising a formulation as described
35 above.

Dry powder inhalers may be particularly useful in the context of the invention as dry vaccine formulations which would be used therein are stable at ambient temperatures.

5 In yet a further aspect, the invention provides the use of microspheres comprising a non-living reagent that produces a protective immune response in a mammal to whom it is administered, in the preparation of a vaccine for administration as an aerosol.

10

Further according to the invention there is provided a method of producing a protective immune response in a mammal in need thereof, said method comprising administering to the lung of said mammal, a protective amount of an aerosol formulation as

15 described above.

The invention will now be particularly described by way of example with reference to the accompanying diagrammatic drawings in which:

20

Figure 1 is a micrograph showing the morphology of microspheres prior to (A) and after (B) nebulization;

25 Figure 2 is a graph showing serum anti-V IgG endpoint titre in 6 BALB/c mice exposed to aerosolised microspheres containing recombinant *Yersinia pestis* V antigen; and

30 Figure 3 illustrates the survival of mice, previously exposed to aerosolised microspheres containing rV antigen, after subcutaneous injection of 6.5 MLDs *Y. pestis*.

Example 1

Poly-lactide (resomer L210) microspheres containing either BSA or recombinant V antigen from *Y. pestis* were fabricated using a 35 modified double-emulsion solvent evaporation process. PLA, sold under the trade name Resomer L210, is a linear crystalline

homopolymer with an inherent viscosity of approximately 3.6. The polymer was used at a concentration of 1.38%w/v in dichloromethane (10ml). An aqueous solution (0.5ml) containing the antigen of interest (about 4mg) was then added and the 5 mixture stirred at high speed to generate an emulsion. This emulsion was then added to a second aqueous phase and mixed together at high speed.

10 The solvent was then evaporated to leave an aqueous suspension of antigen-loaded microspheres.

15 Particles were aerosolised using a Sidestream® nebuliser. An aerosol particle sizer was used to analyse size characteristics. Samples were collected using a three stage liquid impinger and analysed using scanning electron microscopy, SDS PAGE and western blotting procedures.

20 6 female BALB/c mice were exposed to a stream of aerosolised microspheres in a head only exposure line. 77mg of rV loaded microspheres were suspended in 17 ml of free V (at 0.4mg ml⁻¹ in distilled water). Mice were exposed to the aerosolised microspheres for three ten minute runs, during which time approximately 3 ml of particle suspension was nebulized each run. The was repeated on days 0, 21 and 107 of the experiment and sera 25 analysed for the presence of anti-V IgG using an indirect ELISA. In order to assess the extent of protection afforded by inhalation of the V loaded microspheres, mice were injected subcutaneously with 6.3MLDs Y. pestis (GB strain) on day 136 of the experiment.

30

Results and Discussion

Microspheres had a loading of 3.8% w/w (BSA) and 3.3% w/w (rV). Following aerosolisation the BSA loaded particles had a mass median aerodynamic diameter of 1.3± 1.4µm, with 93% of the 35 particles under 3µm. Following nebulisation, particles retained

their morphology/topography (Figure 1) and contained antigenic material as detected by Western Blotting.

Although there was some inter-animal variation in the serum antibody response to aerosolised *Y. pestis* rV antigen, all 6 mice seroconverted after three immunising doses (Figure 2). Two of the six mice responded with antibody titres that were of significant magnitude to confer protection from injected challenge with plague causing bacteria (Figure 3).

Claims

1. An aerosol formulation comprising a biodegradable microsphere comprising a non-living reagent that produces a protective immune response in a mammal to whom it is administered.
2. A formulation according to claim 1 wherein the said non-living reagent is antigenic polypeptide or a nucleic acid sequences which may encode such a polypeptide.
3. A formulation according to claim 2 wherein the said non-living reagent is a sub-unit vaccine.
4. A formulation according to any one of the preceding claims wherein the said non-living reagent is diphtheria toxoid, tetanus toxoid, *Botulinum* toxin FHC, *Bacillus anthracis* protective antigen (PA) or a polypeptide which is capable of generating a protective immune response against *Yersinia pestis*.
5. A formulation according to claim 4 wherein the non-living reagent is the V antigen of *Y. pestis* or an immunologically active fragment thereof or a variant of these, or the F1 antigen of *Y. pestis* or an immunologically active fragment thereof or a variant of these, or a combination of these.
6. A formulation according to any one of the preceding claims wherein the microcapsules are less than 5 μm in average diameter.
7. A formulation according to claim 6 wherein the microcapsules have an average diameter of less than 3 μm .
8. A formulation according to claim 7 wherein the microcapsules have an average diameter of between 1 and 1.5 μm .

9. A formulation according to any one of the preceding claims wherein the microcapsules comprise Poly-lactide (PL).

10. A formulation according to any one of the preceding claims
5 wherein the microcapsules are lyophilised.

11. A formulation according to any one of the preceding claims in unit dosage form.

10 12. A nebuliser or inhaler comprising a formulation according to any one of the preceding claims.

13. The use of microspheres comprising a non-living reagent that produces a protective immune response in a mammal to whom it
15 is administered, in the preparation of a vaccine for administration as an aerosol.


14. A method of producing a protective immune response in a mammal in need thereof, said method comprising administering to
20 the lung of said mammal, a protective amount of an aerosol formulation according to any one of claims 1 to 11.

Abstract**Pharmaceutical Composition**

- 5 An aerosol formulation comprising a biodegradable microsphere comprising a non-living reagent, such as a sub-unit vaccine, that produces a protective immune response in a mammal to whom it is administered.
- 10 Nebulisers and inhalers containing such formulations are also described and claimed.

Figure 1

A



B




Figure 2





Figure 3



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.